Showing results (21-30 of 79) with videos related to
Sort By:
Pageof 8
BJU International|December 13, 2006
Liver metastases in prostate carcinoma: clinical characteristics and outcomeDamien Pouessel, Blandine Gallet, Frédéric Bibeau, et al.Anticancer Research|September 21, 2012
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case seriesStéphane Culine, Zineb Sellam, Linda Bouaita, et al.Bulletin Du Cancer|June 2, 2015
[Molecular biology of castration-resistant prostate cancer]Ludovic Doucet, Safae Terrisse, Hélène Gauthier, et al.Case Reports in Oncological Medicine|August 28, 2014
Concomitant bifocal urothelial carcinoma and breast tumor: second primary cancer or metastatic spread to the breast?Clément Dumont, Hélène Gauthier, Jérôme Vérine, et al.Pathology Oncology Research : POR|September 9, 2016
To Treat or Not to Treat Metastatic Cancer Patients with Poor Performance Status: a Prospective ExperienceTamás Kullmann, Hélène Gauthier, Camille Serrate, et al.Anticancer Research|August 21, 2003
Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary siteDamien Pouessel, Stephane Culine, Catherine Becht, et al.International Journal of Radiation Oncology, Biology, Physics|December 26, 2013
Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trialDavid Azria, Olivier Riou, Xavier Rebillard, et al.Cancer|March 17, 2004
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary siteDamien Pouessel, Stéphane Culine, Catherine Becht, et al.Cancers|August 7, 2021
Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor EraValéry Refeno, Michele Lamuraglia, Safae Terrisse, et al.Journal of Geriatric Oncology|September 28, 2013
Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancerStéphane Culine, Catherine Terret, Didier Cupissol, et al.Pageof 8